The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC).
V. Papadimitrakopoulou
Research Funding - AstraZeneca
J. Heymach
Consultant or Advisory Role - AstraZeneca; Auschon; Boehringer Ingelheim; GlaxoSmithKline; Pfizer
Research Funding - AstraZeneca; GlaxoSmithKline; Pfizer
S. J. Frank
No relevant relationships to disclose
J. Myers
No relevant relationships to disclose
H. Lin
Employment or Leadership Position - M.D. Anderson Cancer Center
H. T. Tran
No relevant relationships to disclose
C. Chen
Research Funding - AstraZeneca
F. R. Hirsch
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; OSI Pharmaceuticals; Roche/Genentech
Other Remuneration - Coinventor of University of Colorado owned patent: EGFR FISH as a predictive marker of EGFR inhibitors
P. B. Langmuir
Employment or Leadership Position - AstraZeneca
J. R. Vasselli
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
S. M. Lippman
No relevant relationships to disclose
D. Raben
Consultant or Advisory Role - Lilly